TIL: Instil Bio, Inc. Stock

by  •  • Comments Off on TIL: Instil Bio, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 67.58
Enterprise Value ($M) 139.81
Book Value ($M) 225.83
Book Value / Share 34.72
Price / Book 0.30
NCAV ($M) 60.96
NCAV / Share 9.37
Price / NCAV 1.11

Profitability (mra)
Return on Invested Capital (ROIC) -0.50
Return on Assets (ROA) -0.37
Return on Equity (ROE) -0.50

Liquidity (mrq)
Quick Ratio 15.22
Current Ratio 15.22

Balance Sheet (mrq) ($M)
Current Assets 160.76
Assets 325.63
Liabilities 99.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -90.54
Net Income -156.09

Cash Flow Statement (mra) ($M)
Cash From Operations -82.03
Cash from Investing 41.13
Cash from Financing 8.08

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-02 13G BML Investment Partners, L.P. 5.30
2023-04-10 13G/A Fmr Llc 0.03 -99.63

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-11-13 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUA
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 282 6,562 4.30
2024-04-25 710 12,120 5.86
2024-04-24 687 2,987 23.00
2024-04-23 131 1,294 10.12
2024-04-22 587 2,744 21.39

(click for more detail)

Similar Companies
TGTX – TG Therapeutics, Inc. THAR – Tharimmune, Inc.
THTX – Theratechnologies Inc. TLSA – Tiziana Life Sciences Ltd
TNXP – Tonix Pharmaceuticals Holding Corp.


Financial data and stock pages provided by
Fintel.io